Past Meeting | Keystone Symposia

This meeting took place in the past. Here is a list of meetings that are related:
	Molecular Approaches to Vaccines and Immune Monitoring (2019J5)
Emerging Technologies in Vaccine Discovery and Development (2018J5)
Translational Vaccinology for Global Health (2017S1)

Web Desc
The Modes of Action of Vaccine Adjuvants Organizer(s): Philippa C. Marrack, Steven Reed and Robert A. Seder Date: October 08 - 13, 2014 Location: Sheraton Seattle Hotel, Seattle, WA, USA Sponsored by Pfizer Inc. Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation. Summary of Meeting: Globally, vaccines are the most effective medical interventions in limiting morbidity and mortality against infections. Effective vaccines are administered in a variety of formulations and include not only portions of their target but also adjuvants. Adjuvants can improve the magnitude and breadth of the immune response and immunological memory against the target and also determine the nature of the generated immune response. Almost all vaccines that are now in use include adjuvants, such as nucleic acids from the target organisms, in the case of attenuated virus vaccines, insoluble aluminum salts (alum), oil-in-water emulsions (MF-59) or formulated toll-like receptor ligands (MPL-TLR4). However, the world still lacks consistently effective vaccines against many infectious agents, tuberculosis, malaria and HIV and against cancers. Therefore much current research is devoted to identification of newer adjuvants, adjuvants that will safely induce the type of immune response that will most effectively deal with its target. In many cases the precise mode of action of the adjuvant is not known. For example the mode of action of alum, an adjuvant that has been used in vaccines since the 1930s and generates excellent antibody responses, is still inadequately understood. This conference will focus on the cell and molecular mechanisms of action of old and new adjuvants and other immunomodulatory agents and their use in various vaccines against infectious diseases and cancer. Global Health Travel Award Deadline: May 6 2014 Scholarship Deadline: June 10 2014 Discounted Abstract Deadline: June 10 2014 Abstract Deadline: July 8 2014 Discounted Registration Deadline: August 7 2014 Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting: We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements: CSL Limited Dynavax Technologies Corporation Novartis Vaccines and Diagnostics We gratefully acknowledge the generous grant for this conference provided by: National Institute of Allergy and Infectious Diseases (NIAID) Grant No. 1R13AI114173-01 The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising: Click here to view more of these organizations Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds: Click here to view more of these organizations

Web Desc

The Modes of Action of Vaccine Adjuvants

Organizer(s): Philippa C. Marrack, Steven Reed and Robert A. Seder

Date: October 08 - 13, 2014
Location: Sheraton Seattle Hotel, Seattle, WA, USA

Sponsored by Pfizer Inc. Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.

Summary of Meeting:

Globally, vaccines are the most effective medical interventions in limiting morbidity and mortality against infections. Effective vaccines are administered in a variety of formulations and include not only portions of their target but also adjuvants. Adjuvants can improve the magnitude and breadth of the immune response and immunological memory against the target and also determine the nature of the generated immune response. Almost all vaccines that are now in use include adjuvants, such as nucleic acids from the target organisms, in the case of attenuated virus vaccines, insoluble aluminum salts (alum), oil-in-water emulsions (MF-59) or formulated toll-like receptor ligands (MPL-TLR4). However, the world still lacks consistently effective vaccines against many infectious agents, tuberculosis, malaria and HIV and against cancers. Therefore much current research is devoted to identification of newer adjuvants, adjuvants that will safely induce the type of immune response that will most effectively deal with its target. In many cases the precise mode of action of the adjuvant is not known. For example the mode of action of alum, an adjuvant that has been used in vaccines since the 1930s and generates excellent antibody responses, is still inadequately understood. This conference will focus on the cell and molecular mechanisms of action of old and new adjuvants and other immunomodulatory agents and their use in various vaccines against infectious diseases and cancer.

Global Health Travel Award Deadline: May 6 2014

Scholarship Deadline: June 10 2014

Discounted Abstract Deadline: June 10 2014

Abstract Deadline: July 8 2014

Discounted Registration Deadline: August 7 2014

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

CSL Limited

Dynavax Technologies Corporation

Novartis Vaccines and Diagnostics

We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI114173-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program


Wednesday, October 08 \| 2:00PM - 7:30PM Keystone Symposia: Arrival and Registration Room: Seattle Sheraton Metropolitan Ballroom Foyer
Wednesday, October 08 \| 3:30PM - 4:00PM Coffee Break Room: Westin Hotel Ballroom Foyer
Wednesday, October 08 \| 4:00PM - 5:00PM Grand Challenges & Keystone Symposia Joint Scientific Sessio n: Innovation Panel Plenary Room: Seattle Westin * Sue Desmond-Hellman, CEO of the Bill & Melinda Gates Foundation - Francis Collins, Director, National Institutes of Health - Bill Gates, Co-Chair of the Bill & Melinda Gates Foundation - Arunachalam Muruganantham, Founder of Jayaashree Industries - Amy Smith, Founder and Co-Director, D-Lab, Massachusetts Institute of Technology
Wednesday, October 08 \| 5:00PM - 6:30PM Grand Challenges & Keystone Symposia: Joint Reception Room: Seattle Westin
Thursday, October 09 \| 7:30AM - 8:30AM Breakfast Room: Metropolitan Ballroom
Thursday, October 09 \| 8:30AM - 11:30AM Cell Death and Nucleic Acids as Adjuvants Room: Metropolitan Ballroom To understand how nucleic acids and other components of the host act as immunological adjuvants. Speaker 1 of 6 * Emilio Flano, Seres Therapeutics, USA
Thursday, October 09 \| 8:30AM - 11:30AM Cell Death and Nucleic Acids as Adjuvants Room: Metropolitan Ballroom To understand how nucleic acids and other components of the host act as immunological adjuvants. Speaker 2 of 6 Michael Gale, Jr., University of Washington, USA Targeting RIG-I for Vaccine Adjuvant Activity
Thursday, October 09 \| 8:30AM - 11:30AM Cell Death and Nucleic Acids as Adjuvants Room: Metropolitan Ballroom To understand how nucleic acids and other components of the host act as immunological adjuvants. Speaker 3 of 6 Ken J. Ishii, National Institute of Biomedical Innovation, Health and Nutrition, Japan Nucleic Acids as 'Built-in' or 'Inducible' Adjuvant during Vaccination
Thursday, October 09 \| 8:30AM - 11:30AM Cell Death and Nucleic Acids as Adjuvants Room: Metropolitan Ballroom To understand how nucleic acids and other components of the host act as immunological adjuvants. Speaker 4 of 6 Anna Marie Pyle, Yale University, USA Small RIG-I Ligands and their Development as Antivirals and Vaccine Adjuvants
Thursday, October 09 \| 8:30AM - 11:30AM Cell Death and Nucleic Acids as Adjuvants Room: Metropolitan Ballroom To understand how nucleic acids and other components of the host act as immunological adjuvants. Speaker 5 of 6 Thomas W. Dubensky, Jr., Tempest Therapeutics, USA Development of Human STING-Activating Synthetic Cyclic Dinucleotide Derivatives as Adjuvants for Cancer Immunotherapy and Infectious Disease
Thursday, October 09 \| 8:30AM - 11:30AM Cell Death and Nucleic Acids as Adjuvants Room: Metropolitan Ballroom To understand how nucleic acids and other components of the host act as immunological adjuvants. Speaker 6 of 6 Robert E. Johnston, Global Vaccines, Inc., USA Short Talk: Biological Adjuvant Activity of Alphavirus Replicon Particles
Thursday, October 09 \| 9:50AM - 10:10AM Coffee Break Room: Metropolitan Ballroom Foyer
Thursday, October 09 \| 11:30AM - 1:00PM Poster Setup Room: Metropolitan Ballroom
Thursday, October 09 \| 11:30AM - 2:30PM On Own for Lunch
Thursday, October 09 \| 1:00PM - 10:00PM Poster Viewing Room: Metropolitan Ballroom
Thursday, October 09 \| 2:30PM - 4:30PM Workshop 1: TLRs and STING Room: Metropolitan Ballroom A Speaker 1 of 8 * Robert R. Kane, Baylor University, USA Synthesis and Protein Conjugation of TLR Agonists
Thursday, October 09 \| 2:30PM - 4:30PM Workshop 1: TLRs and STING Room: Metropolitan Ballroom A Speaker 2 of 8 Aideen C. Allen, Institut de Pharmacologie et de Biologie Structurale, France A Novel TLR2 Agonist from B. pertussis Is a more Effective Adjuvant than Alum for an Acellular Pertussis Vaccine
Thursday, October 09 \| 2:30PM - 4:30PM Workshop 1: TLRs and STING Room: Metropolitan Ballroom A Speaker 3 of 8 Roger H. Brookes, Sanofi Pasteur, Canada Dose-Ranging Analysis of H4 TB Vaccine Formulations in Mouse and Fresh Human Whole Blood Reveal that an Excess of IC31® Adjuvant Is Needed for Immunomodulation
Thursday, October 09 \| 2:30PM - 4:30PM Workshop 1: TLRs and STING Room: Metropolitan Ballroom A Speaker 4 of 8 Mark T. Orr, Infectious Disease Research Institute, USA Mechanistic Insights Into the TH1 Induction Capacity of Formulated TLR4 Agonist Adjuvants
Thursday, October 09 \| 2:30PM - 4:30PM Workshop 1: TLRs and STING Room: Metropolitan Ballroom A Speaker 5 of 8 Caroline Junqueira, Centro de Pesquisas René Rachou/ Fiocruz, Brazil Attenuated Trypanosoma cruzi Expressing Tumor Antigen to Induce a Potent Antitumor Immunity Mediated by TLRs Agonists
Thursday, October 09 \| 2:30PM - 4:30PM Workshop 1: TLRs and STING Room: Metropolitan Ballroom A Speaker 6 of 8 Andres Sanchez Alberti, Universidad de Buenos Aires - CONICET, Argentina Sting Agonist and Antigen Design as a Vaccine Model to Combat Parasitic Chronic Infections
Thursday, October 09 \| 2:30PM - 4:30PM Workshop 1: TLRs and STING Room: Metropolitan Ballroom A Speaker 7 of 8 * Yueh-Ming Loo, AstraZeneca, USA Small Molecule RIG-I Agonists as Vaccine Adjuvants
Thursday, October 09 \| 2:30PM - 4:30PM Workshop 1: TLRs and STING Room: Metropolitan Ballroom A Speaker 8 of 8 Shan Lu, University of Massachusetts Medical Center, USA Involvement of Aim2 Inflammasome Pathway in Antigen Specific Antibody Responses Elicited by HA-Expressing Influenza DNA Vaccine
Thursday, October 09 \| 2:30PM - 4:30PM Workshop 2: T Cells Room: Metropolitan Ballroom B Speaker 1 of 7 * Nancy A. Hosken, University of Washington, USA
Thursday, October 09 \| 2:30PM - 4:30PM Workshop 2: T Cells Room: Metropolitan Ballroom B Speaker 2 of 7 Alicja Misiak, Trinity College Dublin, Ireland Lung gammadelta T Cells Mount Innate and Adaptive Immune Responses to Bordetella pertussis – Implications for Pertussis Vaccines
Thursday, October 09 \| 2:30PM - 4:30PM Workshop 2: T Cells Room: Metropolitan Ballroom B Speaker 3 of 7 Chiung-Yu Hung, University of Texas at San Antonio, USA Th17 Immunity is Essential for Optimal Protection Against Coccidioides Infection
Thursday, October 09 \| 2:30PM - 4:30PM Workshop 2: T Cells Room: Metropolitan Ballroom B Speaker 4 of 7 * Stephen M. Carpenter, Regeneron Pharmaceuticals, USA Heavily-Armed but Outnumbered: A Selective Loss of Memory CD8+ T Cells during Tuberculosis may Eclipse the Benefit of Vaccination
Thursday, October 09 \| 2:30PM - 4:30PM Workshop 2: T Cells Room: Metropolitan Ballroom B Speaker 5 of 7 Dipendra Kumar Mitra, All India Institute of Medical Sciences - AIIMS, India Programed Death Receptor-1 Preferentially Inhibits Poly-Functional T Cells in Human Tuberculosis
Thursday, October 09 \| 2:30PM - 4:30PM Workshop 2: T Cells Room: Metropolitan Ballroom B Speaker 6 of 7 Yasser A. Aldhamen, Michigan State University, USA Therapeutic Blockade of CRACC, a Novel Immune Modulation Strategy for Enhancing Memory T Cell Immune Responses
Thursday, October 09 \| 2:30PM - 4:30PM Workshop 2: T Cells Room: Metropolitan Ballroom B Speaker 7 of 7 Robert Weinkove, Capital & Coast District Health Board, New Zealand Glycolipid-Peptide Conjugates Exploit Natural Killer T Cells to Enhance Peptide-Specific CD8+ T Cell Responses
Thursday, October 09 \| 4:30PM - 5:00PM Coffee Available Room: Metropolitan Ballroom Foyer
Thursday, October 09 \| 5:00PM - 7:00PM The Action of Adjuvants on Dendritic Cell Subsets Room: Metropolitan Ballroom To learn about the use of adjuvants, alone, or in combination with biologicals, in cancer vaccines. Speaker 1 of 4 * Jonathan A. Deane, Kumquat Biosciences, USA
Thursday, October 09 \| 5:00PM - 7:00PM The Action of Adjuvants on Dendritic Cell Subsets Room: Metropolitan Ballroom To learn about the use of adjuvants, alone, or in combination with biologicals, in cancer vaccines. Speaker 2 of 4 Ofer Levy, Boston Children's Hospital, USA In vitro Modeling to Inform Age-Specific Adjuvanted Vaccine Development
Thursday, October 09 \| 5:00PM - 7:00PM The Action of Adjuvants on Dendritic Cell Subsets Room: Metropolitan Ballroom To learn about the use of adjuvants, alone, or in combination with biologicals, in cancer vaccines. Speaker 3 of 4 Claudia Jakubzick, Dartmouth College, USA Short Talk: Dendritic Cell Subsets Require cis-Activation for Cytotoxic CD8 T Cell Induction
Thursday, October 09 \| 5:00PM - 7:00PM The Action of Adjuvants on Dendritic Cell Subsets Room: Metropolitan Ballroom To learn about the use of adjuvants, alone, or in combination with biologicals, in cancer vaccines. Speaker 4 of 4 Karin Loré, Karolinska Institutet, Sweden Innate Immune Activation in vivo after Adjuvant Administration
Thursday, October 09 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Metropolitan Ballroom
Thursday, October 09 \| 7:30PM - 10:00PM Poster Session 1 Room: Metropolitan Ballroom
Friday, October 10 \| 7:30AM - 8:30AM Breakfast Room: Metropolitan Ballroom
Friday, October 10 \| 8:30AM - 11:45AM Immunostimulatory Properties of Particles Room: Metropolitan Ballroom Particles have long been known to have immunostimulatory properties. This session will discuss the mechanisms by which particles have this effect. Speaker 1 of 7 * Rima L. McLeod, University of Illinois, USA
Friday, October 10 \| 8:30AM - 11:45AM Immunostimulatory Properties of Particles Room: Metropolitan Ballroom Particles have long been known to have immunostimulatory properties. This session will discuss the mechanisms by which particles have this effect. Speaker 2 of 7 Tarek M. Fahmy, Yale University, USA Modular Nanomaterials Orchestrating the Direction and Magnitude of the Immune Response
Friday, October 10 \| 8:30AM - 11:45AM Immunostimulatory Properties of Particles Room: Metropolitan Ballroom Particles have long been known to have immunostimulatory properties. This session will discuss the mechanisms by which particles have this effect. Speaker 3 of 7 Gary J. Nabel, Sanofi, USA Synthetic Nanoparticle and Virus-Like Particle Vaccines for Influenza and Alphaviruses: Developing New Technologies to Address Growing Public Health Concerns
Friday, October 10 \| 8:30AM - 11:45AM Immunostimulatory Properties of Particles Room: Metropolitan Ballroom Particles have long been known to have immunostimulatory properties. This session will discuss the mechanisms by which particles have this effect. Speaker 4 of 7 James I. Andorko, University of Maryland, USA Short Talk: Intrinsic Immunogenicity of Rapidly Degradable Polycations: Role of Physicochemical Properties
Friday, October 10 \| 8:30AM - 11:45AM Immunostimulatory Properties of Particles Room: Metropolitan Ballroom Particles have long been known to have immunostimulatory properties. This session will discuss the mechanisms by which particles have this effect. Speaker 5 of 7 Marcela Rincon-Restrepo, École Polytechnique Fédérale de Lausanne, Switzerland Short Talk: Polymersomes Enhance the Induction of Follicular Helper CD4 T Cells and Promote Long Antibody Responses
Friday, October 10 \| 8:30AM - 11:45AM Immunostimulatory Properties of Particles Room: Metropolitan Ballroom Particles have long been known to have immunostimulatory properties. This session will discuss the mechanisms by which particles have this effect. Speaker 6 of 7 Darrell J. Irvine, Massachusetts Institute of Technology, USA Controlling Immunization Potency and Safety through Molecular Targeting of Vaccines to Lymph Nodes
Friday, October 10 \| 8:30AM - 11:45AM Immunostimulatory Properties of Particles Room: Metropolitan Ballroom Particles have long been known to have immunostimulatory properties. This session will discuss the mechanisms by which particles have this effect. Speaker 7 of 7 Steven Reed, Infectious Disease Research Institute, USA Status and Clinical Development of Next Generation of TLR 4 Based Adjuvants
Friday, October 10 \| 9:50AM - 10:10AM Coffee Break Room: Metropolitan Ballroom Foyer
Friday, October 10 \| 11:45AM - 1:00PM Poster Setup Room: Metropolitan Ballroom
Friday, October 10 \| 11:45AM - 2:30PM On Own for Lunch
Friday, October 10 \| 1:00PM - 10:00PM Poster Viewing Room: Metropolitan Ballroom
Friday, October 10 \| 2:30PM - 4:30PM Workshop on Adjuvant Formulation Room: Metropolitan Ballroom A Session to cover three case studies on adjuvant formulation. Co-sponsored by the Global HIV Vaccine Enterprise, the Bill &Melinda Gates Foundation and the Division of AIDS, National Institute of Allergy Infectious Diseases, National Institutes of Health.
Friday, October 10 \| 4:30PM - 5:00PM Coffee Available Room: Metropolitan Ballroom Foyer
Friday, October 10 \| 5:00PM - 7:00PM Lipids, Emulsions and Detergents Room: Metropolitan Ballroom To understand the ways in which these unexpected materials improve immune responses. Speaker 1 of 5 * Christopher B. Fox, Infectious Disease Research Institute, USA
Friday, October 10 \| 5:00PM - 7:00PM Lipids, Emulsions and Detergents Room: Metropolitan Ballroom To understand the ways in which these unexpected materials improve immune responses. Speaker 2 of 5 Yan Shi, University of Calgary, Canada Redirecting MHC Class II Antigen for MHC Class I Crosspresentation during Phagocytosis
Friday, October 10 \| 5:00PM - 7:00PM Lipids, Emulsions and Detergents Room: Metropolitan Ballroom To understand the ways in which these unexpected materials improve immune responses. Speaker 3 of 5 Anja Seubert, GlaxoSmithKline, Italy The Mechanism of Action of the Oil-in-Water Adjuvant MF59
Friday, October 10 \| 5:00PM - 7:00PM Lipids, Emulsions and Detergents Room: Metropolitan Ballroom To understand the ways in which these unexpected materials improve immune responses. Speaker 4 of 5 Eugene Maraskovsky, CSL Limited, Australia Mechanism of Action for Induction of Innate and Adaptive Immune Responses using ISCOMATRIX® Adjuvant
Friday, October 10 \| 5:00PM - 7:00PM Lipids, Emulsions and Detergents Room: Metropolitan Ballroom To understand the ways in which these unexpected materials improve immune responses. Speaker 5 of 5 Anthony L. Desbien, Aduro Biotech, USA Short Talk: A Role for the Inflammasome during Immunization with the TLR4 Agonist GLA when Combined with a Squalene Emulsion
Friday, October 10 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Metropolitan Ballroom
Friday, October 10 \| 7:30PM - 10:00PM Poster Session 2 Room: Metropolitan Ballroom
Saturday, October 11 \| 7:30AM - 8:30AM Breakfast Room: Metropolitan Ballroom
Saturday, October 11 \| 8:30AM - 11:30AM Human Genetics and Adjuvants Room: Metropolitan Ballroom The genetic make up of individuals affects their reponses to vaccines. This issue will be discussed here. Speaker 1 of 6 * Angelika Riemer, German Cancer Research Center /DKFZ, Germany
Saturday, October 11 \| 8:30AM - 11:30AM Human Genetics and Adjuvants Room: Metropolitan Ballroom The genetic make up of individuals affects their reponses to vaccines. This issue will be discussed here. Speaker 2 of 6 Jean-Laurent Casanova, Rockefeller University, USA Toward a Genetic Theory of Childhood Infectious Diseases
Saturday, October 11 \| 8:30AM - 11:30AM Human Genetics and Adjuvants Room: Metropolitan Ballroom The genetic make up of individuals affects their reponses to vaccines. This issue will be discussed here. Speaker 3 of 6 Rafick Sekaly, Emory University, USA Predictors of Adjuvant and Vaccine Efficacy
Saturday, October 11 \| 8:30AM - 11:30AM Human Genetics and Adjuvants Room: Metropolitan Ballroom The genetic make up of individuals affects their reponses to vaccines. This issue will be discussed here. Speaker 4 of 6 Emmanuel Mignot, Stanford University School of Medicine, USA Narcolepsy, Vaccination and Immunogenetics
Saturday, October 11 \| 8:30AM - 11:30AM Human Genetics and Adjuvants Room: Metropolitan Ballroom The genetic make up of individuals affects their reponses to vaccines. This issue will be discussed here. Speaker 5 of 6 Robert L. Coffman, Dynavax Technologies, USA Systems Biology Analysis of the Human Response to Hepatitis B Vaccines using Alum or CpG Oligonucleotide Adjuvants
Saturday, October 11 \| 8:30AM - 11:30AM Human Genetics and Adjuvants Room: Metropolitan Ballroom The genetic make up of individuals affects their reponses to vaccines. This issue will be discussed here. Speaker 6 of 6 Taiki Aoshi, National Institute of Biomedical Innovation, Japan Short Talk: Adjuvant Database Project: Comprehensive Transcriptome Analysis in Animal Models
Saturday, October 11 \| 9:50AM - 10:10AM Coffee Break Room: Metropolitan Ballroom Foyer
Saturday, October 11 \| 11:30AM - 1:00PM Poster Setup Room: Metropolitan Ballroom
Saturday, October 11 \| 11:30AM - 2:30PM On Own for Lunch
Saturday, October 11 \| 1:00PM - 10:00PM Poster Viewing Room: Metropolitan Ballroom
Saturday, October 11 \| 2:30PM - 4:30PM Workshop 3: VLPs and Antigen Presentation Room: Metropolitan Ballroom A Speaker 1 of 8 * Darrell J. Irvine, Massachusetts Institute of Technology, USA
Saturday, October 11 \| 2:30PM - 4:30PM Workshop 3: VLPs and Antigen Presentation Room: Metropolitan Ballroom A Speaker 2 of 8 Rajesh Kumar, Tulane University, USA Plasmodium falciparum Pfs25 Produced in E. coli Delivered with Various Nanoparticles Exhibit Strong Malaria Transmission Blocking Immunity
Saturday, October 11 \| 2:30PM - 4:30PM Workshop 3: VLPs and Antigen Presentation Room: Metropolitan Ballroom A Speaker 3 of 8 Masayuki Hayashi, Mitsubishi Tanabe Pharma, Japan AdvaxTM, a Formulation of Delta Inulin Microparticles, Is a Non-Canonical Adjuvant that Induces Distinct Immune Response Depending on the Property of Vaccine Antigen
Saturday, October 11 \| 2:30PM - 4:30PM Workshop 3: VLPs and Antigen Presentation Room: Metropolitan Ballroom A Speaker 4 of 8 Karen Martins, USAMRIID, USA Impact of Adjuvants on VLP-Mediated Protection from Ebola Virus Challenge
Saturday, October 11 \| 2:30PM - 4:30PM Workshop 3: VLPs and Antigen Presentation Room: Metropolitan Ballroom A Speaker 5 of 8 Marie-Ève Lebel, INRS, Institut Armand Frappier Research Centre, Canada Plant Virus-Like Nanoparticles as Adjuvant: Mechanisms of Action and Application for Cancer Immunotherapy
Saturday, October 11 \| 2:30PM - 4:30PM Workshop 3: VLPs and Antigen Presentation Room: Metropolitan Ballroom A Speaker 6 of 8 Gokul Swaminathan, Merck Research Laboratories Cambridge Exploratory Science Center, USA A Novel Cationic Lipid Nanoparticle Adjuvant Significantly Enhances B Cell and T Cell Responses to Recombinant Sub-Unit Viral Vaccines
Saturday, October 11 \| 2:30PM - 4:30PM Workshop 3: VLPs and Antigen Presentation Room: Metropolitan Ballroom A Speaker 7 of 8 Gervais Rioux, Université Laval, Canada Effect of PapMV Adjuvant on the Immune Response Kinetic of Inactivated Flu Vaccine
Saturday, October 11 \| 2:30PM - 4:30PM Workshop 3: VLPs and Antigen Presentation Room: Metropolitan Ballroom A Speaker 8 of 8 * Elizabeth A. Leadbetter, University of Texas Long School of Medicine, USA Glycolipid Adjuvant-Containing Nanoparticles Protect Against Streptococcus Pneumoniae
Saturday, October 11 \| 2:30PM - 4:30PM Workshop 4: Adjuvant Profiling Room: Metropolitan Ballroom B Speaker 1 of 7 * Mario Barro, Sanofi Pasteur, USA Adjuvants for Novel and More Efficacious Influenza Vaccines
Saturday, October 11 \| 2:30PM - 4:30PM Workshop 4: Adjuvant Profiling Room: Metropolitan Ballroom B Speaker 2 of 7 Christopher B. Fox, Infectious Disease Research Institute, USA Benefits and Limitations of in vitro Human Whole Blood and Macrophage Cell Line Assays to Evaluate Activity of Adjuvant Formulations
Saturday, October 11 \| 2:30PM - 4:30PM Workshop 4: Adjuvant Profiling Room: Metropolitan Ballroom B Speaker 3 of 7 Wivine Burny, GlaxoSmithKline, Belgium Associations between Reactogenicity Symptoms and Parameters of the Early Immune Response to Adjuvanted Vaccines in Humans
Saturday, October 11 \| 2:30PM - 4:30PM Workshop 4: Adjuvant Profiling Room: Metropolitan Ballroom B Speaker 4 of 7 Takuo Mizukami, National Institute of Infectious Diseases, Japan System Vaccinology Enables to Evaluate the Safety of the Influenza Vaccine and the Adjuvant with a Multiplex Gene Detection System of Novel Biomarkers in the Pre-Clinical Study and Lot Release Test
Saturday, October 11 \| 2:30PM - 4:30PM Workshop 4: Adjuvant Profiling Room: Metropolitan Ballroom B Speaker 5 of 7 Jourdan K. Posner, University of Hawaii, Manoa, USA The Effect of Possible Vaccine Adjuvants on the Differentiation and Activation of B Cell Subsets Important to the Germinal Center Reaction
Saturday, October 11 \| 2:30PM - 4:30PM Workshop 4: Adjuvant Profiling Room: Metropolitan Ballroom B Speaker 6 of 7 Katy M. Graef, BIO Ventures for Global Health, USA Accelerating Vaccine Development through Cross-Sector Collaborations
Saturday, October 11 \| 2:30PM - 4:30PM Workshop 4: Adjuvant Profiling Room: Metropolitan Ballroom B Speaker 7 of 7 Emily Field, Loyola University Chicago, USA Developing Adenovirus-Vector Vaccines for MRSA
Saturday, October 11 \| 4:30PM - 5:00PM Coffee Available Room: Metropolitan Ballroom Foyer
Saturday, October 11 \| 5:00PM - 7:00PM Guiding the Immune Response Room: Metropolitan Ballroom Different adjuvants generate different types of immune response. The means by which they do this will be discussed here. Speaker 1 of 5 * Martha A. Alexander-Miller, Wake Forest University School of Medicine, USA
Saturday, October 11 \| 5:00PM - 7:00PM Guiding the Immune Response Room: Metropolitan Ballroom Different adjuvants generate different types of immune response. The means by which they do this will be discussed here. Speaker 2 of 5 Kingston H.G. Mills, Trinity Biomedical Sciences Institute (TBSI), Ireland TLR-Based Adjuvants for Infectious Disease and Cancer Vaccines - Enhancing Effector Over Regulatory T Cell Responses
Saturday, October 11 \| 5:00PM - 7:00PM Guiding the Immune Response Room: Metropolitan Ballroom Different adjuvants generate different types of immune response. The means by which they do this will be discussed here. Speaker 3 of 5 Ross M. Kedl, University of Colorado Denver, USA T Cell Vaccinology: Lessons Learned in Primates
Saturday, October 11 \| 5:00PM - 7:00PM Guiding the Immune Response Room: Metropolitan Ballroom Different adjuvants generate different types of immune response. The means by which they do this will be discussed here. Speaker 4 of 5 Philippa C. Marrack, HHMI/National Jewish Health, USA Host DNA Acts as an Adjuvant in Unexpected Situations
Saturday, October 11 \| 5:00PM - 7:00PM Guiding the Immune Response Room: Metropolitan Ballroom Different adjuvants generate different types of immune response. The means by which they do this will be discussed here. Speaker 5 of 5 Michael Y. Gerner, NIAID, National Institutes of Health, USA Short Talk: Strategically Localized Lymph-Sampling Dendritic Cells Promote Rapid T Cell Responses to Particulate Vaccines and Lymph-Borne Pathogens
Saturday, October 11 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Metropolitan Ballroom
Saturday, October 11 \| 7:30PM - 10:00PM Poster Session 3 Room: Metropolitan Ballroom
Sunday, October 12 \| 7:30AM - 8:30AM Breakfast Room: Metropolitan Ballroom
Sunday, October 12 \| 8:30AM - 12:30PM Adjuvants for Still Unmet Needs Room: Metropolitan Ballroom Here we will discuss the use of old and new adjuvants in new vaccines. Speaker 1 of 8 * Susan Baldwin, Infectious Disease Research Institute, USA
Sunday, October 12 \| 8:30AM - 12:30PM Adjuvants for Still Unmet Needs Room: Metropolitan Ballroom Here we will discuss the use of old and new adjuvants in new vaccines. Speaker 2 of 8 Bali Pulendran, Stanford University School of Medicine, USA Systems Vaccinology: Enabling Rational Vaccine Design with Systems Biology
Sunday, October 12 \| 8:30AM - 12:30PM Adjuvants for Still Unmet Needs Room: Metropolitan Ballroom Here we will discuss the use of old and new adjuvants in new vaccines. Speaker 3 of 8 Lawrence Corey, Fred Hutchinson Cancer Research Center, USA Concepts in the Immunotherapy of HSV 2 Infections Role of Adjuvants
Sunday, October 12 \| 8:30AM - 12:30PM Adjuvants for Still Unmet Needs Room: Metropolitan Ballroom Here we will discuss the use of old and new adjuvants in new vaccines. Speaker 4 of 8 Nathalie Garçon, Bioaster, France Adjuvants for Vaccines against the Big 3: An Historical Perspective
Sunday, October 12 \| 8:30AM - 12:30PM Adjuvants for Still Unmet Needs Room: Metropolitan Ballroom Here we will discuss the use of old and new adjuvants in new vaccines. Speaker 5 of 8 Peter L. Andersen, Statens Serum Institut, Denmark Tailoring Adjuvants for Tuberculosis Vaccines
Sunday, October 12 \| 8:30AM - 12:30PM Adjuvants for Still Unmet Needs Room: Metropolitan Ballroom Here we will discuss the use of old and new adjuvants in new vaccines. Speaker 6 of 8 Derek T. O'Hagan, GlaxoSmithKline Vaccines, USA Can We Design a Single Delivery System for a Broad Range of Molecules from Small Molecule Adjuvants, to Proteins and RNA Vaccines?
Sunday, October 12 \| 8:30AM - 12:30PM Adjuvants for Still Unmet Needs Room: Metropolitan Ballroom Here we will discuss the use of old and new adjuvants in new vaccines. Speaker 7 of 8 Nitasha R. Bennett, University of Wisconsin, Madison, USA Short Talk: Triggering B and T Cell Activation with Synthetic Multivalent Antigens
Sunday, October 12 \| 8:30AM - 12:30PM Adjuvants for Still Unmet Needs Room: Metropolitan Ballroom Here we will discuss the use of old and new adjuvants in new vaccines. Speaker 8 of 8 Michael Fichter, University Medical Center Mainz, Germany Short Talk: Yeast-Based Expression and Purification of Recombinant Hepatitis C Virus Proteins for the Development of Novel Polymeric Protein Nanovaccines
Sunday, October 12 \| 9:50AM - 10:10AM Coffee Break Room: Metropolitan Ballroom Foyer
Sunday, October 12 \| 11:45AM - 2:30PM On Own for Lunch
Sunday, October 12 \| 2:30PM - 4:30PM Workshop 5: Vaccine Mechanisms and Formulations Room: Metropolitan Ballroom A Speaker 1 of 7 * Christopher Jewell, University of Maryland, USA
Sunday, October 12 \| 2:30PM - 4:30PM Workshop 5: Vaccine Mechanisms and Formulations Room: Metropolitan Ballroom A Speaker 2 of 7 Hongming Hu, Providence Cancer Center, USA TLR and NALP3 Inflammasome Dependent Innate Immune Responses to Tumor-Derived Autohagosomes (DRibbles)
Sunday, October 12 \| 2:30PM - 4:30PM Workshop 5: Vaccine Mechanisms and Formulations Room: Metropolitan Ballroom A Speaker 3 of 7 Daniel Villarreal, Advaxis, USA Immunoadjuvant IL-33 Amplifies Memory CD8 T Cells and Enhances Antigen-Specific Tumor and Viral Immunity
Sunday, October 12 \| 2:30PM - 4:30PM Workshop 5: Vaccine Mechanisms and Formulations Room: Metropolitan Ballroom A Speaker 4 of 7 * Arnaud Didierlaurent, University of Geneva, Switzerland Early NK Cell Activation as a Result of MPL and QS-21 Combination Controls the Adjuvant effect Induced by the Human Adjuvant System AS01
Sunday, October 12 \| 2:30PM - 4:30PM Workshop 5: Vaccine Mechanisms and Formulations Room: Metropolitan Ballroom A Speaker 5 of 7 Iain David Welsby, Université Libre de Bruxelles, Belgium Understanding the Cellular and Molecular Mechanisms Involved in the Adjuvanticity of a Liposomal QS-21 Formulation
Sunday, October 12 \| 2:30PM - 4:30PM Workshop 5: Vaccine Mechanisms and Formulations Room: Metropolitan Ballroom A Speaker 6 of 7 Charlotte Givord, Université Libre de Bruxelles, Belgium Deciphering the Signaling Pathways Involved in the Immunostimulatory Properties of the Adjuvant System AS03
Sunday, October 12 \| 2:30PM - 4:30PM Workshop 5: Vaccine Mechanisms and Formulations Room: Metropolitan Ballroom A Speaker 7 of 7 Amy Galliher-Beckley, MFB Fertility, USA Novel Low-Cost, Easy-to-Use Emulsion Is a Stable Adjuvant and Induces Long-Lasting Antibody Responses to Swine Influenza Virus and Mycoplasma hyopneumoniae
Sunday, October 12 \| 2:30PM - 4:30PM Workshop 6: Role of Dendritic Cells in vivo and Dendritic Ce ll Targeting Room: Metropolitan Ballroom B Speaker 1 of 9 * Ross M. Kedl, University of Colorado Denver, USA
Sunday, October 12 \| 2:30PM - 4:30PM Workshop 6: Role of Dendritic Cells in vivo and Dendritic Ce ll Targeting Room: Metropolitan Ballroom B Speaker 2 of 9 * Richard A. Kroczek, Robert Koch-Institute, Germany Targeting of Antigen into XCR1+ Dendritic Cells Combined with a Non-Viral Boost Regime Induces Massive CD8+ T Cell Cytotoxicity Capable of Controlling 50xLD50 Listeria Infection and Eradicating Established Tumors
Sunday, October 12 \| 2:30PM - 4:30PM Workshop 6: Role of Dendritic Cells in vivo and Dendritic Ce ll Targeting Room: Metropolitan Ballroom B Speaker 3 of 9 Monica Montes, Baylor Institute for Immunology Research, USA Anti-Human CD40 Antibodies with Selective Functional Properties
Sunday, October 12 \| 2:30PM - 4:30PM Workshop 6: Role of Dendritic Cells in vivo and Dendritic Ce ll Targeting Room: Metropolitan Ballroom B Speaker 4 of 9 Rossella Cioncada, University of Siena, Italy Vaccine Adjuvant MF59 Promotes in vivo Differentiation of Monocyte-Derived Dendritic Cells within Medullary Compartment of the Draining Lymph Nodes, which Correlates with Increased Ability to Trigger T Cell Response
Sunday, October 12 \| 2:30PM - 4:30PM Workshop 6: Role of Dendritic Cells in vivo and Dendritic Ce ll Targeting Room: Metropolitan Ballroom B Speaker 5 of 9 Stefaan De Koker, University of Gent, Belgium Inflammatory DCs Constitute a Crucial Source of IL-12 but Fail to Present Antigen in Case of CpG-Adjuvanted Vaccines
Sunday, October 12 \| 2:30PM - 4:30PM Workshop 6: Role of Dendritic Cells in vivo and Dendritic Ce ll Targeting Room: Metropolitan Ballroom B Speaker 6 of 9 Laura E. Noges, Fred Hutchinson Cancer Research Center, USA Host DNA Plays a Role in Generating CD4 T Cell Responses to Various Vaccine Adjuvants
Sunday, October 12 \| 2:30PM - 4:30PM Workshop 6: Role of Dendritic Cells in vivo and Dendritic Ce ll Targeting Room: Metropolitan Ballroom B Speaker 7 of 9 Elizabeth A. Thompson, Karolinska Institute, Sweden Intravenous Administration of an Agonistic CD40 Antibody Induces Strong T Cell Responses in the Lung
Sunday, October 12 \| 2:30PM - 4:30PM Workshop 6: Role of Dendritic Cells in vivo and Dendritic Ce ll Targeting Room: Metropolitan Ballroom B Speaker 8 of 9 Chinnaswamy Jagannath, Houston Methodist Research Institute, USA Induction of Autophagy as an Emerging Molecular Mechanism of Immunoadjvants
Sunday, October 12 \| 2:30PM - 4:30PM Workshop 6: Role of Dendritic Cells in vivo and Dendritic Ce ll Targeting Room: Metropolitan Ballroom B Speaker 9 of 9 Frédéric Martinon, INSERM U1184 Commissariat Energie Atomique (CEA) - Université Paris-Saclay, France TLR Ligands Indirectly Activate Skin Langerhans Cells by Triggering Local Recruitment of Inflammatory Cells
Sunday, October 12 \| 2:30PM - 4:30PM Workshop 7: Vaccine Delivery Room: Ravenna Speaker 1 of 6 Tarek Hamouda, NanoBio Corp., USA Intranasal Nanoemulsion-Adjuvanted Genital Herpes Vaccine; A New Approach Utilizing Mucosal Immunity to Induce Protection Against HSV2 Infections
Sunday, October 12 \| 2:30PM - 4:30PM Workshop 7: Vaccine Delivery Room: Ravenna Speaker 2 of 6 * Olivia M. Flynn, University College Cork, Ireland Immunogenicity of dmLT Adjuvanted Vaccines in ImmuPatch Dissolvable Microneedle Patches in Mice
Sunday, October 12 \| 2:30PM - 4:30PM Workshop 7: Vaccine Delivery Room: Ravenna Speaker 3 of 6 Chintan Hareshbhai Kapadia, University of North Carolina at Chapel Hill, USA PRINT Nanoparticulate Subunit Vaccine to Combat Cancer
Sunday, October 12 \| 2:30PM - 4:30PM Workshop 7: Vaccine Delivery Room: Ravenna Speaker 4 of 6 Sudhir Pai Kasturi, Emory University, USA Programming the Magnitude and Persistence of Humoral Immunity Against HIV Using Novel TLR Ligands Delivered in Biodegradable Nanoparticles
Sunday, October 12 \| 2:30PM - 4:30PM Workshop 7: Vaccine Delivery Room: Ravenna Speaker 5 of 6 Kouji Kobiyama, National Institute of Biomedical Innovation, Japan K3-SPG, a Nano-Particulate TLR9 Agonistic Ligand Works as a Potent IFN Inducer and CTL Adjuvant
Sunday, October 12 \| 2:30PM - 4:30PM Workshop 7: Vaccine Delivery Room: Ravenna Speaker 6 of 6 * Aaron Palmer Esser-Kahn, University of California, Irvine, USA Controlling Adjuvant Activity with Light
Sunday, October 12 \| 4:30PM - 5:00PM Coffee Available Room: Metropolitan Ballroom Foyer
Sunday, October 12 \| 5:00PM - 6:30PM New Approaches to Vaccines Room: Metropolitan Ballroom Speaker 1 of 3 * Laura Shackelton, Bill & Melinda Gates Foundation, USA
Sunday, October 12 \| 5:00PM - 6:30PM New Approaches to Vaccines Room: Metropolitan Ballroom Speaker 2 of 3 Jenny P.Y. Ting, University of North Carolina at Chapel Hill, USA Impact of NLR Proteins on Innate and Adaptive Immunity
Sunday, October 12 \| 5:00PM - 6:30PM New Approaches to Vaccines Room: Metropolitan Ballroom Speaker 3 of 3 Robert A. Seder, NIAID, National Institutes of Health, USA Adjuvants for HIV Vaccines, Mice versus Humans
Sunday, October 12 \| 6:30PM - 7:00PM Meeting Wrap-Up: Outcomes and Future Directions (Organizers) Room: Metropolitan Ballroom
Sunday, October 12 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Metropolitan Ballroom
Sunday, October 12 \| 8:00PM - 11:00PM Entertainment Room: Metropolitan Ballroom
Sunday, October 12 \| 8:00PM - 11:00PM Cash Bar Room: Metropolitan Ballroom
Monday, October 13 \| 10:25AM - 10:25AM Departure *Session Chair.